Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genomma Lab InternacionalB de CVMEX:LABB -1.32%64 Capex-to-Operating-Income is 0.14 as of Jun. 2026, which is 250% above its 10-year median of 0.04. GuruFocus rates MEX:LABB with a GF Score™ of 64/100 and a GF Value™ of MXN17.29 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 499 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks better than 97.39% on this metric.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Genomma Lab InternacionalB de CV (MEX:LABB) Capex-to-Operating-Income Explanation
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Genomma Lab InternacionalB de CV Capex-to-Operating-Income Related Terms
Genomma Lab InternacionalB de CV Capex-to-Operating-Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Capex-to-Operating-Income Chart
MEX:LABB vs ZTS, UTHR, VTRS: Capex-to-Operating-Income Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Capex-to-Operating-Income vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Capex-to-Operating-Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Income of 0.14 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Capex-to-Operating-Income of 0.14 as of Jun. 2026. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 250% above median its historical median of 0.04. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #13 out of 499 companies in the Drug Manufacturers industry, placing it in the top 2.6%.
Is Genomma Lab InternacionalB de CV's Capex-to-Operating-Income too high?
Genomma Lab InternacionalB de CV's current Capex-to-Operating-Income of 0.14 is 250% above median its 10-year median of 0.04. The Drug Manufacturers industry median Capex-to-Operating-Income is 0.39. Genomma Lab InternacionalB de CV's value of 0.14 is 64.1% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #13 out of 499 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Capex-to-Operating-Income compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #13 out of 499 companies for Capex-to-Operating-Income. This places Genomma Lab InternacionalB de CV in the top 3% of its industry — outperforming the majority of peers. The industry median Capex-to-Operating-Income is 0.39. Genomma Lab InternacionalB de CV's value of 0.14 is 64.1% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.39, Genomma Lab InternacionalB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Income for a Drug Manufacturers company?
The median Capex-to-Operating-Income among Drug Manufacturers companies is 0.39, based on 499 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Income significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Capex-to-Operating-Income of 0.14 is 64.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Income mean?
A high Capex-to-Operating-Income can signal that a stock is expensive relative to its fundamentals. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Capex-to-Operating-Income is 0.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Capex-to-Operating-Income is 0.14, which is 250% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.29, compared to a current price of MXN12.74 — trading 26.3% below its estimated fair value. The current Capex-to-Operating-Income is 0.14, which is 250% above median its 10-year median of 0.04 and 64.1% below the Drug Manufacturers industry median of 0.39. Genomma Lab InternacionalB de CV's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Income calculated?
Capex-to-Operating-Income is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Capex-to-Operating-Income is 0.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN12.74 is trading 26.3% below its estimated GF Value™ of MXN17.29.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Capex-to-Operating-Income: 0.14 (250% above median its 10-year median of 0.04)
GF Value™: MXN17.29 vs. price of MXN12.74 (26.3% below fair value)
Industry Position: 64.1% below the Drug Manufacturers median (#13 of 499)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
64GF Score
Get the complete analysis for MEX:LABB
Capex-to-Operating-Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
